Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
131I-apamistamab · 1 trial · 11 indications
| Name | Type | Description |
|---|---|---|
| 131I-apamistamab | DRUG | Iodine-131 radiolabeled anti-CD45 monoclonal antibody (apamistamab). Administered IV as a dosimetric dose followed by treatment dose. |
| Fludarabine | DRUG | Fludarabine phosphate, 30 mg/m² IV daily on Days -6 through -2. |
| Cyclophosphamide | DRUG | Cyclophosphamide |
| Total Body Irradiation (TBI) | RADIATION | TBI, 200 cGy on Day -1 prior to HSCT. |
| Allogeneic Hematopoietic Stem Cell Transplant (HSCT) | BIOLOGICAL | Unmodified, G-CSF-mobilized donor stem cells infused on Day 0. |
131I-apamistamab is an investigational monoclonal antibody-based radioimmunotherapy developed by Actinium Pharmaceuticals, Inc. (ATNM). It is being studied as a conditioning regimen before allogeneic transplant in patients with acute leukemia, including relapsed or refractory acute myeloid leukemia. It combines a monoclonal antibody with the radioisotope iodine-131.
131I-apamistamab is being developed for use in acute leukemia, specifically as radioimmunotherapy conditioning before allogeneic transplant in patients with relapsed or refractory acute myeloid leukemia. The Phase 2/Phase 3 study enrolls patients with AML in relapse or refractory AML, along with related myeloid leukemia conditions.
131I-apamistamab is developed by Actinium Pharmaceuticals, Inc., which trades under the ticker ATNM. The company is sponsoring the clinical program evaluating the agent as a conditioning approach for allogeneic transplant in acute leukemia.
131I-apamistamab is in Phase 3 development. Its single registered trial, NCT07157514, is listed as Phase 2/Phase 3 and is not yet recruiting. The drug is investigational and has not been approved by the FDA for any indication.
131I-apamistamab is being studied in one registered clinical trial, NCT07157514, titled Radioimmunotherapy Conditioning With 131I-Apamistamab for Allogeneic Transplant in Relapse/Refractory AML. The trial is Phase 2/Phase 3, has a planned enrollment of 306 participants, and is currently not yet recruiting.
131I-apamistamab is a monoclonal antibody-based radioimmunotherapy, meaning it pairs an antibody with the radioisotope iodine-131. It is designed to deliver targeted radiation as a conditioning regimen before allogeneic transplant in patients with relapsed or refractory acute myeloid leukemia.